Random Posts
- Enjoy Your Diabetic Holiday Meals Without Going Out of Control
- Diet Precautions For Diabetics
- Here Are the Major Signs of High Blood Sugar
- What is the Function of the Pancreas and How it Affects Diabetes
- Is Diabetes Research Focussed on the Right Goal?
- Creating a Diet Plan For Your Diabetes
- What Causes Diabetes is Not a Myth
- How to Choose the Best Foods to Include in Diets For Diabetics
Prescription Diabetes Drugs
Posted by admin in Prescription Diabetes Drugs on May 31st, 2009
Vildagliptin provides similar glycated hemoglobin (HbA1c) reductions to metformin but with superior gastrointestinal tolerability in drug-naïve elderly patients with Type 2 diabetes, research shows.
Elderly people with diabetes are a challenging population to treat because of an increased risk for renal impairment, a high number of comorbidities and concomitant drug use, and a high prevalence of cardiovascular risk factors.
In the first study with vildagliptin to be conducted exclusively in Type 2 diabetes patients aged at least 65 years, Anja Schweizer (Novartis Pharma AG, Basel, Switzerland) and colleagues compared its efficacy and tolerability with that of metformin.
The 24-week study included 335 patients with an HbA1c of 7??”9% who had not received oral glucose-lowering agents for more than 3 consecutive months at any time in the past and no agents for at least 12 weeks prior to screening.
Patients were randomly assigned to receive vildagliptin 100 mg daily (given as a once-daily dose) or metformin titrated to a maximum of 1500 mg daily (given as 1000 mg in the morning and 500 mg in the evening).
The results, reported in the journal Diabetes, Obesity and Metabolism, show that patients receiving vildagliptin achieved similar HbA1c reductions to those taking metformin, at 0.64% and 0.75%, respectively, from baseline, and establish non-inferiority of vildagliptin to metformin.
As expected, the decrease in HbA1c with either agent was greater in patients with a baseline HbA1c greater than 8%, with mean HbA1c reductions from baseline of 0.93% with vildagliptin) and 1.02% with metformin.
Body weight decreased with both agents, although to a greater degree with metformin (0.45 kg versus 1.25 kg, respectively).
One or more adverse events were reported by 44.3% of patients receiving vildagliptin and 50.3% of patients receiving metformin. A low incidence of hypoglycemia was observed in both treatment groups.
In patients receiving vildagliptin, the most frequent adverse events were nasopharyngitis and dizziness, whereas gastrointestinal events were more frequently reported with metformin.
“We conclude that vildagliptin is effective and well tolerated in drug-naïve elderly patients with Type 2 diabetes in whom it could represent a valuable treatment option,” write the authors.
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a part of Springer Science+Business Media. © Current Medicine Group Ltd; 2009
- Living With Charcot Foot & Diabetic Neuropathy Requires Support
- Diet Can Control Diabetes - Proper Diet is a Must If You Want to Stop Diabetes From Getting Worse
- No sign of native beta-cell regeneration in Type 1 islet or pancreas allograft recipients
- A Fresh Approach in How to Manage Type 2 Diabetes Symptoms - Just What You Have Been Looking For
- Reduce Blood Sugar in Style
- Diabetes Menu Plans
- Tips and Ideas on Reversing Diabetes Naturally
- Myths About High Blood Sugar Levels - Read These, Relax, Take Intelligent Action
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.